Biocon Limited informed that in reference to the proposed acquisition of biosimilars assets of Viatris Inc., by Biocon Biologics Limited (BBL), a subsidiary of the company. BBL has allotted equity shares to Biocon Limited for an amount of Rs2,205.63 crore (~US$ 270 million) on November 23, 2022.
Biocon Limited's stake in BBL will be 88.85% following the allotment of shares.
BBL is a one-of-a-kind, globally integrated biosimilars organisation. It is leveraging cutting-edge science, innovative technology platforms, and advanced research and development capabilities to reduce biologics therapy costs while improving healthcare outcomes.
It has a robust biosimilar molecules research pipeline in diabetes, oncology, immunology, and other non-communicable diseases. BBL, with a team of over 5,000 people, is dedicated to transforming healthcare and lives by providing affordable access to millions of patients worldwide.
At around 9.17 AM, Biocon was trading at Rs276.70 up by 0.99% from its previous closing of Rs274 on the BSE.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.